Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance
Several studies have demonstrated that IFN-I administration can boost anti-tumor immune response against solid tumors. Here, to overcome the limitations of systemic IFN-I therapy (side effects, short half-life), the authors design a masked IFN-I prodrug activatable by tumor-associated proteases, sho...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/8b56982268c24d6785de4d9f98953a35 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|